STAR COMBO PHARMA LIMITED

Annual General Meeting

CEO Presentation

Su Zhang | Chief Executive Officer

24 November 2026

FY26 Key results

$23.57M
Revenue
FY26

$18.0M
Year-end cash
30 June 2026

$400K
Fully franked dividend
Paid 31 October 2026

Operational highlights

- Revenue $23.57 Million
- Retail Division has been closed to cut the loss
- Rebuilt factory #2 has been completed in June 2026.
- Production efficiencies continue to improve
- Strong cash position at 30 June 2026 and continuing
- Fully Franked Dividend of $400,000 paid on 31 October 2026

FY26 group financial performance

AUD	FY26 $000's	FY25 $000's	FY24 $000's
OEM revenue	$23,195	$25,820	$23,400
Retail revenue	$378	$1,986	$2,660
Group revenue	$23,573	$27,812	$26,019
Profit / (loss) before tax	$528	$5,313	$1,001

FY26 group financial performance

AUD	FY26 Full year $000's	FY25 Full year $000's	FY24 Full year $000's
External sales	$23,573	$27,812	$23,343
Profit from operations	$1,319	$6,395	$1,277
Depreciation & amortisation	($791)	($1,082)	($276)
Profit / (loss) before tax	$528	$5,313	$1,001

OEM division update

24
New customer accounts
In the last 12 months

Gummies
Product formats
Successfully commercialised

Strong
FY27 order book

Manufacturing

- OEM division has again performed well
- 24 new customer accounts have been established in the last twelve months.
- At the date of this report the group order book for the FY 2027 remains strong.
- Gummy products have been successfully commercialised
- The following new products have been developed and are available for further commercialisation going forward
    - Liquid products
    - APVMA products
- Distribution agreement continues in Vietnam for supply of Costar products throughout the country

OEM Production efficiencies

Production indicator	FY2026	FY2025
Capsules / tablets manufactured	463,930,190	520,314,600
Batches manufactured	332	324
Actual production time (hrs)	57,316	60,872
Potential production time (hrs)	78,489	78,489
Production OEE	73.02%	77.55%

Facilities improvements

Building 1	Main manufacturing facility and commercial offices — maintained to a high standard.
Building 2+	Gummy and packaging lines operational; soft-gel line completed.
Building 3	Warehouse — maintained to a high standard.

Retail division update

1. The retail division was significantly impacted by the market downturn and has required some significant restructuring and impairment of assets in FY23.

2. Physical retail stores that the business operated in Carlingford and Ashfield in Sydney were closed in September 2022 with all sales transferred online.

3. 49% of the business was sold to members of the customer service team in November 2022.

Due to the continuing loss, the Retail Division was closed in November 2025 and no Retail revenues have been earned since that date.

Cash position

$18.0M
FY26 year-end cash
30 June 2026

$18.1M
FY25 year-end cash
30 June 2025

$7.4M
FY24 year-end cash
30 June 2024

Cash flow (AUD)	2026 $M's	2025 $M's	2024 $M's
Cash at start of year	$18.1	$7.4	$9.5
Cash at end of year	$18.0	$18.1	$7.4
Capital expenditure	$2.4	$0.4	$1.4

FY27 Q1



Strategic focus

- During FY2026 the Group is continuing its focus on implementing and transitioning its strategy to become a leading contract manufacturer in Australia for the vitamin and health supplements sector.
- Cash position remained strong at 30 September 2026
- Fully franked dividend paid on 31 October 2026

x

Our people

People

Our team continues to execute the strategy of becoming a leading Australian nutraceutical manufacturer.

Safety

As a manufacturing business, we are dedicated to ensuring we have a safe workplace.

The company has in place a comprehensive occupational health and safety program which all staff are required to follow.

Wellbeing

A comprehensive WHS plan has been implemented at Star Combo.

Significant precautions and protocols are in place to safeguard the health and wellbeing of our employees.

Achievements & outlook

FY26 achievements	The contract manufacturing division remained strong and continued to perform well	Operating cash flow positive; $18M in cash in bank	Retail business closed
2027 outlook	Contract manufacturing remains the strategic focus	Contract manufacturing outlook remains resilient benefiting from strong macro trends	New market development opportunities providing potential for growth
2027 opportunities	Increase gummy manufacturing capability and sales	Commence manufacture of pet supplements, utilising the recently acquired license granted by the Australian Pesticides and Veterinary Medicines Authority (APVMA)	



Investor relations
investors@starcombo.com.au

THANK YOU

DISCLAIMER

The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This presentation provides information in summary form and general information regarding Star Combo Pharma Ltd ACN 615 728 375 (Star Combo or the Company) and the proposed placement to sophisticated and professionalinvestors.

This presentation contains information, ideas and analysis which are proprietary to Star Combo. By agreeing to receive this information you also agree to respect the confidential nature of this entire presentation. Specifically you agree not to reproduce in any manner any part of the information contained herein without our prior written consent. This presentation is not complete, is intended only as an outline and has been prepared by and issued by Star Combo to assist in informing interested parties about the Company and should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation.

This presentation is current as at the date on the cover page. The information in this presentation, therefore, remains subject to change. The Company is under no obligation to update the presentation and the information in this presentation remains subject to change by the Company in its absolute discretion and withoutnotice.

This presentation may contain forward looking statements. Whilst the Company has no reason to believe that any such statements are either false, misleading or incorrect, it cannot and does not warrant or guarantee that through either the passage of time or actions beyond the control of the company they will not become so. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This overview of investment does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

The Company's statutory results are prepared in accordance with International Financial Reporting Standards ("IFRS"). This presentation also includes certain non-IFRS measures in presenting the Company's results. Any additional financial information in this presentation which is not included in the Company's 30 June 2018 Financial Statements was not subject to independent audit or review. Investors should be aware that certain financial data included in this presentation is "non-IFRS financial information" under ASIC Regulatory Guide 230: "Disclosing non-IFRS financial information" published by ASIC and may also be "non-GAAP financial information" within the meaning given under Regulation G of the U.S. Securities Exchange Act of 1934, as amended.

Non-IFRS financial information does not have a standardised meaning prescribed by Australian Accounting Standards ("AAS"). Accordingly, the non-IFRS financial information in this presentation: (i) may not be comparable to similarly titled measures presented by other entities; (ii) should not be construed as an alternative to other financial measures determined in accordance with AAS; and (iii) is not a measure of performance, liquidity or value under the IFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial information included in this presentation.

Tothe maximum extent permitted by law, the Company and its advisers make no representation and give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility and assume no liability for,the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omissions, from any information, statement or opinion contained in this presentation. All values are expressed in Australian currency unless otherwise stated.

This presentation is not for release to US wire services or distribution in the United States or any country where it may be unlawful. See "International Offer Restrictions".